News & Promotions

Provide total solutions for Life Science applications together with global partners. We are constantly striving to be more
connected, forward-looking and customer-focused to deliver best results.

News & Promotions


[EDI] Novel Coronavirus COVID-19 ELISA Kits Overview and Assay Protocols

관리자 2021.03.29 10:23 조회 1110 추천 21






Overview  //  Technical Specifications  //  Protocols //  Instructions for Use // Publications // Frequently Asked Questions


Overview & Statement on the Mutations


The 2019 Novel Coronavirus (COVID-19) is a single-stranded RNA coronavirus. Comparisons of the genetic sequences of this virus have shown similarities to SARS-CoV and other bat coronaviruses. In humans, coronaviruses cause respiratory infections.  Coronaviruses are composed of several proteins including the spike (S), envelope (E), membrane (M), and nucleocapsid (N). It has been suggested that the spike protein has sufficient affinity to the angiotensin converting enzyme 2 (ACE2) receptor to use it as a mechanism of cell entry. Human-to-human transmission of coronaviruses is primarily thought to occur among close contacts via respiratory droplets generated by sneezing and coughing. There are over 90,000 confirmed Coronavirus cases globally with over 3,000 deaths as a direct result of the infection.

Effective detection of the coronavirus is extremely critical. Currently, real-time polymerase chain reaction (RT-PCR) tests detect genetic material to perform coronavirus testing. However, these tests have low rates of specificity and sensitivity and pose risks related to specimen collection and sample handling. Epitope Diagnostics, Inc. has developed a solution to minimize these risks by using IgG and IgM ELISA kits. IgG is the most abundant immunoglobulin to be produced in response to an antigen and is maintained in the body after initial exposure for long term response. IgM is the first immunoglobulin to be produced in response to an antigen and is primarily detected during the early onset of disease.

Serological IgG and IgM test for COVID-19 B.1.1.7 and B.1.351 Lineages

The recent UK SARS-CoV-2 variant called VUI*202012/01 (B.1.1.7 lineage) has accumulated multiple gene mutations in the spike protein. Five are amino acid replacements (D614G, A222V, N439K, Y453F and N501Y), and one deletion (del). The South African variant called 501.V2 (B.1.351 lineage) also has gene mutations in the spike protein: D80A, D215G, E484K, N501Y and A701V. Although the full significance of these mutations is yet to be determined, experts believe that mutations in the receptor spike protein fit the virus invasion to the host.

Do these mutations affect Epitope Diagnostics’ serological IgG and IgM Coronavirus ELISAs (KT-1032, KT-1033 and KT-1034)?

Epitope Diagnostics’ Novel COVID-19 IgG and IgM assays are designed to identify human IgG and IgM reacting to multiple epitopes of SARS-CoV-2 full length Nucleocapsid protein, therefore the mutations in spike protein of the B.1.1.7 and the B.1.351 lineages variants do not impact the safety and effectiveness of Epitope Diagnostics’ COVID-19 IgG and IgM tests.

Epitope Diagnostics’ Proactive Risk Management Plan:

Epitope Diagnostics informs its distributors and laboratories to analyze and report any suspect test results that do not meet clinical findings. EDI monitors SARS-CoV-2 variants databases in NCBI, GISAID and SARS-CoV-2 publications (PubMed). The information is used to perform thorough bioinformatics analysis quarterly. Based on in silico analysis, the performance of the kit is not impacted by the mutations.


Assay Protocols



Frequently Asked Questions

  1. What type of test is this?

    This is an enzyme linked immunosorbent assay (ELISA) test. It is a serological plate-based assay technique designed for detecting and quantifying substances such as peptides, proteins, antibodies and hormones. This test is not the same as PCR or Rapid Test.


  2. Why not use PCR and Rapid Tests?

    Polymerase Chain Reaction (PCR) is a diagnostic test designed to confirm a clinical disease through the amplification of DNA and RNA. However, PCR can only achieve a sensitivity of 50 to 79%, presents issues during the isolation of the virus from clinical specimen, and requires biosafety level 3 laboratory facilities. Rapid Test Diagnostics (RTD) are lateral-flow assays, that use a dipstick or cassette format to perform a qualitative detection of a disease. However, due to the format of the assay, they can only achieve a sensitivity of 30%. For these reasons, Epitope Diagnostics, Inc. does not offer either of these tests for the detection of COVID-19.


  3. How do I use your tests?

    The kit contains a 96-well ELISA microtiter plate and all the reagents and control materials required to run the test. Each kit can run up to 92 patient samples in singlet, or 46 in duplicate depending on the preference of the laboratory. Tests can be performed manually with any spectrophotometric microplate reader capable of reading absorbance at 450 nm and a ELISA multichannel wash bottle or automatic (semi-automatic) washing system. Assays can be performed on automated instruments with additional validation.


  4. What Biosafety Level should I be using and what guidelines should I be following?

    The Centers for Disease Control and Prevention (CDC) has recommended using BSL-2. Please refer to their guidance Interim Laboratory Biosafety Guidelines for Handling and Processing Specimens Associated with Coronavirus Disease 2019 (COVID-19) for more information.



The EDI™ Novel Coronavirus COVID-19 IgG ELISA Kit, EDI™ Novel Coronavirus COVID-19 IgM ELISA Kit, and EDI™ COVID-19 Nucleocapsid IgG Quantitative ELISA Kit are available now!




(주)엘바이오시스템은 Epitope Diagnostics Inc.(EDI)의 한국공식대리점 입니다.

 제품의 주문 및 관련 정보가 필요하시면 전화, 팩스, 이메일로 문의해 주세요.